Telehealth Prescribing Fraud: Who Controlled the Clinical Decision?

Telehealth prescribing fraud happens when a platform pushes prescriptions without a medical basis and uses false statements to get the drugs dispensed and paid for. The prescription carries a clinician’s signature. Behind it sits a company rule controlling which patients the clinician sees, what information arrives, what earns payment and what happens after a refusal. If you worked in prescribing, clinical operations, pharmacy support or billing, you may have seen the rule that made the signature possible.

What Are Some Examples of Prescription Fraud?

False prior authorizations, fabricated patient records and misleading statements to pharmacies are examples of prescription fraud alleged in the criminal indictment concerning Done. Prosecutors alleged that the subscription platform used those representations to get Adderall and other stimulants dispensed, generate insurance payments and keep members paying monthly fees.

The Justice Department’s July 2026 account of Done’s criminal trial reports that its founder and clinical president were convicted in November 2025 of controlled-substance offenses and a health care fraud conspiracy. The trial evidence included prescribing pressure, automatic refills, misleading pharmacy assurances and ignored warnings.

When Payment Follows the Prescription

Telehealth prescribers paid only when a patient gets a prescription have a financial reason to write it. The compensation policy shows what management wanted its clinicians to produce.

The Done indictment alleged that the company paid prescribers solely according to the number of patients for whom they wrote prescriptions each month. It also alleged that Done refused to pay for consultation time or medical services after the initial consultation. The instruction quoted in the filing was to “use the comp structure to dis-encourage follow-up”. The prescription generated compensation. The work of checking the patient afterward did not.

When a telehealth platform refuses to pay follow-up consultations, the compensation policy belongs beside the clinical schedule. Who could book a return visit, who performed it and whether that work appeared in the payment ledger show how the policy operated.

Cerebral admitted a different set of prescribing incentives in its November 1, 2024 criminal non-prosecution agreement. It set a 95% prescription target for all medication-management initial visits. A separate ADHD initiative sought near-100% stimulant prescribing for patients without comorbidities, meaning other conditions occurring alongside ADHD. Cerebral also admitted different staff payments for controlled and noncontrolled prescriptions.

If a telehealth prescription approval quota appears in a dashboard or a manager’s message, we compare it with the clinical decisions and compensation it was meant to influence. Cerebral’s admissions give that inquiry a specific starting point: management had selected a desired prescribing rate before the individual clinical decisions were made.

The target and the actual prescribing results belong beside each other. Cerebral’s internal November 2021 data showed that 52.7% of 2,128 ADHD clients without comorbidities received stimulants. Its initial-visit prescribing metric did not improve after December 2021 despite the pressure. A later internal analysis attributed additional prescribing to the ADHD campaign. We compare the company’s assessment with the patients and prescriptions behind each metric.

When the Platform Controls the Information

The assessment depends on what the clinician can see and what the platform expects the clinician to accept. Intake design, questionnaire changes and access to prior records can put management’s decisions inside the clinical encounter.

The Done indictment alleged that management limited information available to prescribers and instructed them to prescribe Adderall and other stimulants even when a member did not qualify. It also alleged that the company promoted its intake screening as the reason it could diagnose ADHD faster, although people unlikely to have ADHD could still schedule appointments. The claimed screening was part of the sales pitch and part of the explanation for the clinical workflow.

The indictment also alleged that leadership continued its practices after learning of online instructions for obtaining easy access to stimulants through Done, member overdoses and deaths, and public scrutiny. We examine who received those warnings, what instructions reached clinicians afterward and which prescriptions followed. That comparison connects management’s knowledge to its later decisions about prescribing.

In a separate False Claims Act complaint, a nurse practitioner alleged that Cerebral moved its diagnostic quiz from video visits to patient self-completion before the visit and pressured prescribers to rely on the results.

State professional boards examine the clinical relationship too. In a May 2023 Mississippi board order, the board found that a physician’s questionnaire and instant-message encounters failed to establish a sufficient relationship.

Refusals, Bridge Prescriptions and Automatic Refills

A clinician’s refusal can expose who controlled the next decision. Cerebral’s criminal agreement documented thousands of duplicate accounts and provider reassignment after prescription refusals. We connect the patient’s history across accounts, the earlier refusal and the next prescription, including whether the next prescriber received the earlier clinical decision.

The Done indictment alleged that bridge prescriptions went through replacement prescribers who had never examined the members in person or consulted with them by video. Those replacement prescribers then allegedly issued Adderall and other stimulant prescriptions without either kind of encounter. The transfer kept the prescription moving.

Separately, the Justice Department’s account of evidence at Done’s criminal trial described its clinical president prescribing 394,324 Schedule II stimulant pills to 6,559 members he had never evaluated and whose records he had not reviewed. That makes the assignment history and access to records central to understanding who made the decision.

A telehealth company’s automatic refill request without patient contact raises another concrete question: who requested it? The indictment alleged that Done’s system automatically generated a request in the member’s name and that its policy did not require follow-up encounters. The company could generate the request that appeared to come from the patient.

For a clinician or software employee, the relevant sequence runs from the original prescription through the refill trigger, any patient communication, the assigned prescriber and the next signed order. Refusal notes and reassignment history can show where the decision changed.

The Prescription Continues to the Pharmacy and Payer

A platform can influence a prescription again when it answers the pharmacy’s questions or seeks an insurer’s approval. Prior authorizations and pharmacy communications carry representations about the patient and the care that produced the order.

The Done indictment alleged that false prior authorizations and pharmacy assurances helped secure drug dispensing and claims to Medicare, Medicaid and commercial insurers.

Patients paid Done a monthly subscription fee while insurers paid for the drugs, according to the indictment. The alleged scheme put patients on prescriptions without a medical basis and left taxpayers paying the government-program claims.

For pharmacy-support and billing employees, the connection is between the clinical decision, the pharmacy’s account and the paid claim.

The broader order business follows a similar payment path. In its July 2022 telemedicine fraud alert, the Department of Health and Human Services’ Office of Inspector General described marketers, call centers, staffing companies and practitioners assembling orders for businesses that bill federal programs. The order can generate the downstream bill even when the ordering clinician never bills for a remote visit. In prescription cases, the pharmacy and insurer records complete that financial picture.

Who Controlled the Clinical Decision?

Control shows up in the decisions about intake, scheduling, compensation, patient assignment, refills and pharmacy responses. The brand on the screen, the professional practice and the billing business may hold different parts of that history.

Telehealth businesses can sell access, completed encounters, software or recurring treatment subscriptions. Each arrangement creates a different payment record. The contract, invoice, encounter log and clinician’s compensation show what the business was actually paid to deliver. A subscription ledger shows the recurring commercial relationship. The clinical record shows the work performed for the patient.

The Cerebral whistleblower complaint made that connection explicitly as an allegation. It alleged that continuing Adderall prescriptions required frequent telehealth visits, creating an economic opportunity the company pursued. It also alleged that a prescribing inducement affected federally reimbursed prescriptions, subscriptions, mental-health appointments and medication-management appointments. That was the complaint’s theory of how prescribing incentives reached government money.

A 2024 Rutgers University Law Review analysis, Plausible Cause: Connecting the FCA and AKS in the Context of Health Care Fraud, points to companies’ own analyses and knowledge of their billing processes as important evidence connecting incentives to claims. An insider may know why a target changed or why a refusal led to reassignment. That knowledge gives the records their context.

The False Claims Act Follows Government Payment

For a telehealth prescribing whistleblower case, we connect what happened clinically to the statements used to obtain government payment. We examine the operating rule, what the prescription or claim represented, who understood the difference and which program paid.

The timing of the care matters too. The federal temporary prescribing framework extends qualifying remote controlled-substance prescribing through December 31, 2026. Remote prescribing still needs a real medical reason.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Your knowledge of how a platform turned its prescribing policy into paid claims is what we work through with you.

When You Know Why the Prescription Went Through

If you saw a prescribing target, an unpaid follow-up policy or a refusal overturned through reassignment, talk with our whistleblower experts about the decisions behind those prescriptions. We work beside you to connect the clinical decisions, company incentives and government payments into your strongest telehealth whistleblower case. We bring in healthcare fraud whistleblower lawyers who understand prescribing and pharmacy claims, and stay with you through the case.